Weight-loss drugs like Ozempic and Wegovy are becoming increasingly popular among Americans, but their impact could extend well beyond personal health. New research suggests that GLP-1s could influence everything from hiring decisions to workplace productivity. Meanwhile, employers are facing questions about whether covering these expensive medications is worth the cost, and whether the potential benefits for their workforce justify the investment.
New research examines how GLP-1 drugs could affect the labor market
Weight-loss drugs like Ozempic and Wegovy are becoming increasingly popular among Americans, but their impact could extend well beyond personal health. New research suggests that GLP-1s could influence everything from hiring decisions to workplace productivity. Meanwhile, employers are facing questions about whether covering these expensive medications is worth the cost, and whether the potential benefits for their workforce justify the investment.
Same Story from Other Publications
Compare how 4 other independent news outlets reported on this story.
Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.
FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss
The risk appears small and data is mixed, but FDA wants patients to be aware.
‘Feeling really weak and shaky’: Experts warn of malnutrition risks on GLP-1s
Rapid weight loss can trigger hair loss, heart complications and vitamin deficiencies if nutrient needs go unmet, health experts have warned.
Doctors explain GLP-1 side effects | CNN
Two doctors explain the big mistakes that cause GLP-1 side effects. Watch the full episode at CNN.com/BodyLanguage.
Related Stories
Business & Economy